Personalized Medicine, Targeted Therapeutics: Jsbmarketresearch

Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015

Released On 16th September 2015

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages.

The personalized medicine (global) market is presented as follows:

• By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)

• By Geography (US, UK, EU)

• By Segment (Targeted therapeutics, Companion Diagnostics, Esoteric tests, Esoteric lab services)

• By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)

A wealth of financial data & business strategy information is provided including:

• Company financials, sales & revenue figures

• Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies

• Business Model Strategies for Providers. Provider Systems and Academic Medical Centres

• Business Model Strategies for Payers & Governments

• Private and Public Funding and Personalized Medicine Reimbursement

• Revisions to Current Payment Systems and intellectual property

• How to Gain Market Penetration in the EU

• Cost-effectiveness and Business Value of Personalized Medicine

• Consumer genomics and POC market

• Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)

• Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market

• Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)

• Top fastest growing market segments and emerging opportunities

• Top pharmaceutical companies within the...